IL17A and depressive symptom measurement: In the pathological condition of psoriasis, systemic IL‐17A elevation can trigger microglia activation, provoke pro‐inflammation mediators release, evoke neural inflammation effects, then inhibit hippocampal neurogenesis and result in depression development.